Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor

Abstract

Open access

Peer reviewed

S.H. Kizilbash, A. El-Khoueiry, R.E. Lerner, P.C. Ma, M. Almubarak, K. Mody, M.E. Burkard, M. Guarino, J. Jenab-Wolcott, N. Sankar, …

European journal of cancer (1990), Vol.138, pp.S11-S12

10/2020

DOI: 10.1016/S0959-8049(20)31095-9

Files and links (1)

url

https://doi.org/10.1016/S0959-8049(20)31095-9View

Published (Version of record) Open Access

Title: Subtitle: Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor
Creators: S.H. Kizilbash - Mayo Clinic in Arizona
A. El-Khoueiry - USC Norris Comprehensive Cancer Center
R.E. Lerner - Park Nicollet Clinic
P.C. Ma - Pennsylvania State University
M. Almubarak - Virginia Cancer Institute
K. Mody - Mayo Clinic in Florida
M.E. Burkard - University of Wisconsin Carbone Cancer Center
M. Guarino - Christiana Care Health System
J. Jenab-Wolcott - Christiana Care Health System
N. Sankar - Apollomics
G. Choy - Apollomics
L. Espiritu - Apollomics
X. Zhang - Apollomics
A. Luria - Apollomics
F. Benedetti - Apollomics
E.C. Dees - University of North Carolina at Chapel Hill
Resource Type: Abstract
Publication Details: European journal of cancer (1990), Vol.138, pp.S11-S12
Publisher: Elsevier Ltd
DOI: 10.1016/S0959-8049(20)31095-9
ISSN: 0959-8049
eISSN: 1879-0852
Language: English
Date published: 10/2020
Academic Unit: Internal Medicine
Record Identifier: 9984701251202771

1 Record Views